Schizophrenia - Articles - Page 7

Tips on Choosing an Antipsychotic for Schizophrenia

August 26, 2020

Which antipsychotics should we consider selecting as the first-line and second-line treatments, and what should we base this decision on? Dr. Aziz addresses this in a past article from The Carlat Psychiatry Report. Here’s some of his advice:Process: Tolerability instead of efficacy should be considered when selecting a first-line treatment.

A Potentially Lethal Side Effect You Probably Never Heard Of

May 7, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA recently raised alerts about a potentially fatal side effect on clozapine that’s causing more fatalities than neutropenia. It’s constipation, and the problem extends to a few other psychotropics as well. In this article, a three step, evidence-based algorithm for managing it.

How to Choose an Antipsychotic in Schizophrenia

March 30, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.

Polypharmacy in Schizophrenia

February 10, 2020

Jason Mallo, DO

Jason Mallo, DO. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Polypharmacy is often practiced in schizophrenia, but you have to look hard to find any evidence that it helps. These two large-scale studies lend some empiric support to the practice, but also give us insights into how it could go wrong.

Highlights From This Issue

November 15, 2019

Quick hits on what you’ll find in this issue.

Evaluating the Mortality Risks of Antipsychotics in Children and Youths

March 13, 2019

There are reports of increased mortality from antipsychotics in older adults. Now, we have a paper showing increased mortality in children, adolescents, and young adults aged 5–24 years. Given the frequent use, both on- and off-label, of antipsychotics, does this change how we use them? And if so, how?

Cannabidiol for Schizophrenia

January 1, 2019

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this pilot study, investigators evaluated the benefits of cannabidiol (CBD), which is one of the two main active components of marijuana (the other being THC), for the treatment of schizophrenia.

EXPERT Q&A

The Neurobiology of Schizophrenia

March 1, 2009

Fredrik Jarskog, MD

Fredrik Jarskog, MD. Associate Professor of Clinical Psychiatry, Chief of Clinical Therapeutics Lieber Center for Schizophrenia Research and Treatment New York State Psychiatric Institute/Columbia University.

Dr. Jarskog has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jarskog has disclosed that glycine, D-serine, D-cycloserine, and Glu2/3 receptor agonists are not FDA-approved for the treatment of schizophrenia.

Dr. Jarskog, for many years the dopamine theory of schizophrenia has been dominant in the field. What is the current status of that theory?